000276825 001__ 276825
000276825 005__ 20250318091451.0
000276825 0247_ $$2doi$$a10.1016/j.parkreldis.2025.107318
000276825 0247_ $$2pmid$$apmid:39913957
000276825 0247_ $$2ISSN$$a1353-8020
000276825 0247_ $$2ISSN$$a1873-5126
000276825 037__ $$aDZNE-2025-00338
000276825 041__ $$aEnglish
000276825 082__ $$a610
000276825 1001_ $$aKrauss, Jonas$$b0
000276825 245__ $$aBeyond the cerebello-thalamo-cortical tract: Remote structural changes after VIM-MRgFUS in essential tremor.
000276825 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000276825 3367_ $$2DRIVER$$aarticle
000276825 3367_ $$2DataCite$$aOutput Types/Journal article
000276825 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1740395528_19529
000276825 3367_ $$2BibTeX$$aARTICLE
000276825 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276825 3367_ $$00$$2EndNote$$aJournal Article
000276825 520__ $$aEssential tremor (ET) is a progressive disorder characterized by altered network connectivity between the cerebellum, thalamus, and cortical regions. Magnetic Resonance-guided Focused Ultrasound (MRgFUS) of the ventral intermediate nucleus (VIM) is an effective, minimally invasive treatment for ET. The impact of MRgFUS interventions on regional Gray Matter Volume (GMV) are as yet not well understood.Forty-six patients with medication-resistant ET underwent unilateral VIM-MRgFUS. Voxel-based morphometry was applied to investigate GMV changes over a time span of 6 months in the whole brain and the thalamus in particular to investigate local and distant effects.Clinically, contralateral tremor significantly decreased by 68 % at 6 months following MRgFUS. In addition to local GMV decreases in thalamic nuclei (VIM, ventral lateral posterior, centromedian thalamus and pulvinar), VBM revealed remote GMV decreases in the ipsilesional insula and the anterior cingulate cortex as well as the contralesional middle occipital gyrus. Increased GMV was found in the right superior and middle temporal gyrus, as well as in the left inferior temporal gyrus. There was no significant correlation between regional GMV declines and tremor improvement. However, temporal volume increases were associated with improved motor-related functional abilities and quality of life outcomes.Our findings implicate distributed structural changes following unilateral VIM-MRgFUS. Structural losses could reflect Wallerian degeneration of VIM output neurons or plasticity due to decreased sensory input following tremor improvement.
000276825 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276825 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276825 650_7 $$2Other$$aEssential tremor
000276825 650_7 $$2Other$$aMRgFUS
000276825 650_7 $$2Other$$aStructural changes
000276825 650_7 $$2Other$$aVBM
000276825 650_7 $$2Other$$aVIM
000276825 650_2 $$2MeSH$$aHumans
000276825 650_2 $$2MeSH$$aEssential Tremor: therapy
000276825 650_2 $$2MeSH$$aEssential Tremor: diagnostic imaging
000276825 650_2 $$2MeSH$$aEssential Tremor: pathology
000276825 650_2 $$2MeSH$$aFemale
000276825 650_2 $$2MeSH$$aMale
000276825 650_2 $$2MeSH$$aAged
000276825 650_2 $$2MeSH$$aVentral Thalamic Nuclei: diagnostic imaging
000276825 650_2 $$2MeSH$$aMiddle Aged
000276825 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000276825 650_2 $$2MeSH$$aCerebral Cortex: diagnostic imaging
000276825 650_2 $$2MeSH$$aCerebral Cortex: pathology
000276825 650_2 $$2MeSH$$aGray Matter: diagnostic imaging
000276825 650_2 $$2MeSH$$aGray Matter: pathology
000276825 650_2 $$2MeSH$$aNeural Pathways: diagnostic imaging
000276825 650_2 $$2MeSH$$aNeural Pathways: pathology
000276825 650_2 $$2MeSH$$aCerebellum: diagnostic imaging
000276825 650_2 $$2MeSH$$aCerebellum: pathology
000276825 650_2 $$2MeSH$$aHigh-Intensity Focused Ultrasound Ablation: methods
000276825 650_2 $$2MeSH$$aThalamus: diagnostic imaging
000276825 650_2 $$2MeSH$$aThalamus: pathology
000276825 7001_ $$0P:(DE-2719)2812558$$aUpadhyay, Neeraj$$b1$$udzne
000276825 7001_ $$0P:(DE-2719)9000867$$aPurrer, Veronika$$b2$$udzne
000276825 7001_ $$aBorger, Valeri$$b3
000276825 7001_ $$0P:(DE-2719)2811028$$aDaamen, Marcel$$b4$$udzne
000276825 7001_ $$0P:(DE-2719)2810830$$aSchmitt, Angelika$$b5$$udzne
000276825 7001_ $$0P:(DE-2719)9001551$$aSchmeel, Carsten$$b6
000276825 7001_ $$0P:(DE-2719)9001861$$aRadbruch, Alexander$$b7$$udzne
000276825 7001_ $$0P:(DE-2719)2000056$$aWüllner, Ullrich$$b8$$udzne
000276825 7001_ $$0P:(DE-2719)2810726$$aBoecker, Henning$$b9$$eLast author$$udzne
000276825 773__ $$0PERI:(DE-600)2027635-7$$a10.1016/j.parkreldis.2025.107318$$gVol. 132, p. 107318 -$$p107318$$tParkinsonism & related disorders$$v132$$x1353-8020$$y2025
000276825 8564_ $$uhttps://pub.dzne.de/record/276825/files/DZNE-2025-00338.pdf$$yOpenAccess
000276825 8564_ $$uhttps://pub.dzne.de/record/276825/files/DZNE-2025-00338.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276825 909CO $$ooai:pub.dzne.de:276825$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000276825 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812558$$aExternal Institute$$b1$$kExtern
000276825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000867$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000276825 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811028$$aExternal Institute$$b4$$kExtern
000276825 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810830$$aExternal Institute$$b5$$kExtern
000276825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001861$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000276825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000056$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000276825 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810726$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000276825 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276825 9141_ $$y2025
000276825 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000276825 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276825 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPARKINSONISM RELAT D : 2022$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276825 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000276825 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000276825 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000276825 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x1
000276825 9201_ $$0I:(DE-2719)5000075$$kAG Radbruch$$lClinical Neuroimaging$$x2
000276825 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x3
000276825 980__ $$ajournal
000276825 980__ $$aVDB
000276825 980__ $$aUNRESTRICTED
000276825 980__ $$aI:(DE-2719)1011202
000276825 980__ $$aI:(DE-2719)1011001
000276825 980__ $$aI:(DE-2719)5000075
000276825 980__ $$aI:(DE-2719)1011302
000276825 9801_ $$aFullTexts